Treatment effectiveness and safety
We aim to understand disease progression and prognosis for people living with musculoskeletal disease.
We do this by exploring:
- biologic, biosimilar and new targeted therapies;
- conventional synthetic anti-rheumatic drugs and glucocorticoids;
- analgesics for chronic musculoskeletal pain; non-pharmacological treatments.
The MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS) project (2015-2021) identified predictors of response to drugs in systemic lupus erythematosus (SLE) patients.